Key result
Ximelagatran compared to warfarin for the prevention of atrial fibrillation-related stroke presents both clinical benefits and risks.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
Requires careful risk-benefit weighing before ximelagatran use in AF; leaves open its role versus warfarin pending higher-level evidence.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Testa et al. (2007) studied this question. Ximelagatran compared to warfarin for the prevention of atrial fibrillation-related stroke presents both clinical benefits and risks.
Synapse has enriched 10 related papers. Consider them for comparative context: